NCT05897138View on ClinicalTrials.gov

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle

"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV